Biocitech welcomes new researchers from Pharma Omnium International
Biocitech announces the amalgamation on its campus of the anti-infective research teams of Pharma Omnium International, a French pharmaceutical company specialized in research into anti-infectives.
Pharma Omnium International has considerably stepped up its research effort over the past 12 months by taking over two French biotech firms – Mutabilis in June 2009 and Cellvir in May this year. The group’s research programs are focused on two major underlying markets, namely the treatment of severe bacterial infections in general and hospital-acquired infections in particular, and therapies to combat viruses, especially Aids.
The Mutabilis researchers, who were already working on the Biocitech campus, will be merged with those from Cellvir, which is moving into new, superbly equipped facilities in Biocitech. The Pharma Omnium research center resulting from this amalgamation comprises 35 researchers, biologists, microbiologists, virologists, biochemists and medical chemists, all specialized in research into anti-infectives.
“We are delighted to welcome all the research teams of Pharma Omnium International to our campus, which is specialized in life sciences and has become a Mecca for anti-infective specialists,” said the President of Biocitech, François Boussard. “The arrival of these new researchers rounds off the range of anti-infective research already being carried out by residents of the park.”
Other news from the department business & finance
